Consistently, in a study of advanced NSCLC treated with ICIs, fewer pretreatment peripheral blood CD8+ T-cells were also associated with durable clinical benefit (accuracy = 70%) (28). This evidence concerns the gene CD8A and non-small cell lung carcinoma.